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3 -4 - 8 Determination by enzymatic assay is time-consuming and requires a large quantity of fresh cells/' This makes it difficult to perform terminal deoxynucleotidyl transferase determinations, in many cases, because of the inability to obtain sufficient numbers of cells. Such a situation arises when the leukemic process is unexpected, or when the marrow aspirate is impossible or difficult to obtain. A technic utilizing unstained bone marrow smears or touch preparations would provide an easier and more rapid means for this determination. We have evaluated a new procedure using indirect immunofluorescence for terminal deoxynucleotidyl transferase determination in order to investigate its value in examining bone marrow smears and touch preparations from patients with a wide variety of hematologic oncologic disorders.
Materials and Methods
One hundred and fifty-six consecutive bone marrow aspirates were evaluated for terminal deoxynucleotidyl transferase positivity. Touch preparations were examined when bone marrow aspirate smears were inadequate or unobtainable. Several patients had peripheral blood smears studied simultaneously. Surface marker studies were performed when possible, as previously described. 13 
Slide Immunofluorescence
Peripheral blood, bone marrow smears, or bone marrow touch preparations were air-dried on glass slides. All specimens tested were less than 14 days old. The slides were fixed in methanol at 4 C for 30 min and then processed for indirect immunofluorescence. Fixed slides were hydrated in phosphate-buffered saline solution (PBS) for 5 min at room temperature; then, 15 /xl of primary antibody (rabbit anti-calf TdT) were placed on an area containing an even distribution of hematopoietic cells and incubated for 30 min in a humid chamber. The slides were washed three times for 15 min in PBS and reincubated for 30 min with 15 ju.1 of the secondary antibody, fluorescein isothiocyanate (FITC), coupled to goat anti-rabbit-IgG F(ab') 2 fragments. The slides were washed three times in PBS TERMINAL TRANSFERASE IMMUNOFLUORESCENCE 899
Fio. 1. (left)
Bone marrow of patient with leukemic phase of T-cell lymphoma (immunofluorescence). x400.
FIG. 2 (right).
Bone marrow of patient with chronic myelogenous leukemia in blast crises, "lymphoid" (immunofluorescence). x400.
for 15 min and mounted with FA® mount, pH 9.5 (Difco). All specimens were examined with a Zeiss photomicroscope III, with an epifluorescent attachment and narrow band-pass filters. Automatic-exposure photography was used with Kodak Ektachrom 200® daylight professional film (ASA 800), or Kodak Tri-X® (ASA 1600). At least five fields were counted (approximately 500 cells in bone marrow smears) and cells with fluorescent nuclei were scored as positive. Positive cells were expressed as percentages of total leukocytes observed in the same field under phase microscopy.
Antisera
The properties and preparation of antisera to homogeneous calf terminal deoxynucleotidyl transferase have been described. 7 An IgG fraction of rabbit antiterminal deoxynucleotidyl transferase (Lot #52) was rendered highly specific by eluting from a controlledpore glass column containing covalently attached terminal deoxynucleotidyl transferase 1 and used for immunofluorescence at a concentration of 100 ju,g protein per ml in PBS. FITC coupled to goat anti-rabbit-IgG (F[ab'] 2 fragment) was prepared and used at the same concentration.
Results
Cells with terminal deoxynucleotidyl transferase activity demonstrated nuclear fluorescence (Figs. I and 2). The bone marrows from patients with lymphoblastic leukemias showed more than 44% cells positive for terminal deoxynucleotidyl transferase (Table I ). This included five typical cases of acute lymphoblastic leukemia (ALL) and three cases of the leukemic phase ofa lymphoma. Surface marker studies were performed on cells from two of the typical cases of acute lymphoblastic leukemia and were shown to be non-T, non-B cells. All three cases of the leukemic phase of lympho-900 STASS ETAL, A.J.C.P. . December 1979 blastic lymphoma were demonstrated to be of T-cell origin by surface marker studies. A high percentage of terminal deoxynucleotidyl transferase-positive cells was also observed in two additional rather unusual cases. In one case, lymphoblastic morphologic features and a moderate proportion of myeloid precursors were found in the bone marrow. Cytogenetic analysis revealed a double Philadelphia chromosome. Special stains showed a myeloid and lymphoid population. Terminal deoxynucleotidyl transferase-positive cells by phase-contrast microscopy had a high nuclearxytoplasmic ratio and thus appeared lymphoblastic. The positive terminal deoxynucleotidyl transferase supported the lymphoid nature of these blasts. The patient was considered to have chronic myelogenous leukemia (CML), presenting as acute leukemia (lymphoid). The second case demonstrated a leukemic bone marrow, with the blasts showing lymphoid morphologic features and markedly positive terminal deoxynucleotidyl transferase. Less than 5% blasts were positive for Sudan black B and myeloperoxidase, but the majority of the blasts were positive for periodic acid-Schiff (PAS), /3-glucuronidase, and acid phosphatase, and strongly positive for terminal deoxynucleotidyl transferase. A rare cell contained an Auer rod that was Sudan black B and myeloperoxidase positive. The bone marrows of all patients with lymphoblastic leukemia had less than 1% terminal deoxynucleotidyl transferasepositive cells when morphologic evidence of remission (less than 5% blasts) was identified by use of WrightGiemsa stain (Table 2) , except for two patients with 6% terminal deoxynucleotidyl transferase-positive cells who have not shown evidence of relapse for six months (Table 1) .
Three additional cases were found in the range of 5-25% terminal deoxynucleotidyl transferase-positive cells. The first was that of a patient with 25% terminal deoxynucleotidyl transferase-positive immature cells and a hypoplastic marrow. A stem cell leukemia with a hypercellular marrow rapidly developed. The terminal deoxynucleotidyl transferase-positive blast cells were totally undifferentiated on electron microscopy, with minimal heterochromatin. All special stains and examinations had negative results, including peroxidase, light and electron microscopy, Sudan black B, acid phosphatase, and PAS. The second case was that of a patient with chronic myelogeneous leukemia, with 2 -9% terminal deoxynucleotidyl transferase activity, in whom the disease appears to be evolving into a blast crisis. The third case was that of a patient with idiopathic sideroblastic anemia of three years' duration (9% terminal deoxynucleotidyl transferase-positive cells). Be- (Table 2) .
Discussion
Terminal deoxynucleotidyl transferase has become a valuable marker of lymphoid tumors, and therefore is used in the diagnosis of leukemias 3 and may be useful in the diagnosis of lymphoblastic lymphomas. It has also been helpful in identifying leukemias of pre-B cells 14 and rare cases of acute myelogenous leukemia." The technic described, using indirect immunofluorescence, is rapid and requires only routine smears, in contrast to the more laborious enzymatic assay, which also requires fresh cells. 6 In addition, air-dried smears In the majority of non-lymphoid-tumor cases, the smears demonstrate less than 1% activity, except for a small, nonspecific group (Table 2) . This correlates well with the previous findings of low levels of terminal deoxynucleotidyl transferase in nonlymphoid tumors, as determined by enzymatic assay. 6 -10 This is particularly evidenced by the presence of more than 44% activity in all cases of acute lymphoblastic leukemia and in the leukemic phases of T-cell lymphoblastic lymphomas in our series. Remission states of acute lymphoblastic leukemia showed less than 1% terminal deoxynucleotidyl transferase-positive cells, except for two cases in which the patients are being closely followed to detect possible relapses. Although terminal deoxynucleotidyl transferase determinations by enzymatic assay were not done in the present series, previous studies have shown a high degree of correlation between results of enzymatic assay and indirect immunofluorescence in the majority of cases. 2 It is important to note that in three cases of acute lymphoblastic leukemia in which aspirate smears were unavailable because of "dry taps," touch preparations of the bone marrow biopsies were available and provided adequate material for the terminal deoxynucleotidyl transferase determinations. Peripheral blood smears of leukemias with circulating blasts were also positive for terminal deoxynucleotidyl transferase. This could help to differentiate atypical lymphocytes from leukemic lymphoblasts. It might also permit earlier diagnosis and indicate the necessity for bone marrow examination. Although all terminal deoxynucleotidyl transferase determinations reported were performed on slide specimens less than 14 days old, in our experience, specimens from cases of acute lymphoblastic leukemia as much as ten months old have given activity consistent with acute lymphoblastic leukemia. Difficulties in preservation of cellular morphologic integrity have been a problem in performing indirect immunofluorescence tests on aged specimens, and we do not recommend use of this kind of material for diagnostic work.
The use of terminal deoxynucleotidyl transferase determinations in all cases of leukemia has yielded findings that may have an impact on the future classification of leukemia or interpretation of terminal deoxynucleotidyl transferase-positive cases, or both. This is evidenced by the finding of terminal deoxynucleotidyl transferase activity in a specimen from a patient with acute leukemia who had Auer rods in rare myeloblasts cells. 12 The appropriate treatment regimen for this type of patient needs further clarification. A second patient had chronic myelogenous leukemia and was initially seen for treatment in a lymphoid blast crisis. This patient showed a favorable response to Vincristine® and prednisone (as previously described). 9 Terminal deoxynucleotidyl transferase determinations may have important prognostic implications, as demonstrated by the case of the patient who had a hypoplastic marrow with terminal deoxynucleotidyl transferase activity when first seen, in whom acute stem cell leukemia rapidly developed. This case suggests that terminal deoxynucleotidyl transferase positivity in hypoplastic bone marrows may give initial evidence that there could be a leukemic transformation. This may be an extremely valuable prognostic finding, and may alert the clinician to those cases in which leukemia might ultimately develop. This should be be evaluated by a study of a larger, retrospective series.
Terminal deoxynucleotidyl transferase activity in bone marrows of patients with acute lymphoblastic leukemia who appear on the basis of results obtained with the Wright-Giemsa stain to be in morphologic remission may raise the suspicion that in these patients the disease will evolve into a state of relapse. We are following two such patients closely. It is possible that terminal deoxynucleotidyl transferase activity may slowly increase in patients who have chronic myelogenous leukemia before the disease evolves into a blast crisis. We are following such a patient who has a 2 -9 % range of terminal deoxynucleotidyl transferase positivity in the bone marrow, maturation arrest, and resistance to chemotherapy.
In addition to the obvious clinical applications of elevated terminal deoxynucleotidyl transferase positivity, further information may be derived from the indirect immunofluorescent technic, such as the intensity of nuclear staining and its relation to other lymphoid markers. Our initial experience that T-cell lymphoproliferative disorders give a more intense nuclear immunofluorescent staining than null-cell processes should be confirmed by additional studies.
From the immunofluorescent data and results of earlier studies using enzymatic activity, it can be concluded that terminal deoxynucleotidyl transferase may be far-reaching importance as a diagnostic marker. Detection of termination deoxynucleotidyl transferase in cells by indirect immunofluorescence of air-dried smears gives satisfactory and rapid results useful in the diagnosis of lymphoblastic tumors. The convenience of this technic should provide a simpler and more rapid means for terminal deoxynucleotidyl transferase determinations than the enzymatic assay.
